S-1/A: Aptevo Therapeutics Seeks Up to $4.6 Million in Public Offering to Advance Cancer Immunotherapy Pipeline

Aptevo Therapeutics is launching a public offering of common stock and warrants to raise capital for its clinical programs and general corporate purposes, focusing on advancing its immunotherapy candidates for cancer treatment.

Summary

• Aptevo Therapeutics Inc. has filed an amendment to its Form S-1 registration statement for a proposed public offering.
• The offering includes up to 922,509 shares of common stock, pre-funded warrants for up to 922,509 shares, and common warrants for up to 1,845,018 shares.
• Each share of common stock or pre-funded warrant is offered with two common warrants, each exercisable for one share of common stock.
• The assumed combined public offering price is $5.42 per share and common warrant, based on the closing price of Aptevo's common stock on March 15, 2024.
• Pre-funded warrants are offered to purchasers who would exceed beneficial ownership limits of 4.99% or 9.99% of outstanding common stock.
• The exercise price for pre-funded warrants is $0.0001 per share.
• Common warrants have an exercise price of $ per share and expire five years from issuance.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering.
• The company estimates net proceeds of approximately $4.6 million from the offering, intending to use them for working capital and general corporate purposes, including the development of product candidates.
• The offering will terminate no later than April 20, 2024, unless terminated earlier at Aptevo's discretion.
• Investors will experience immediate and substantial dilution in the net tangible book value per share.
• There is no established public trading market for the pre-funded warrants or common warrants.

Sentiment

Score: 6

Explanation: The document is primarily factual, outlining the details of a public offering. While the offering itself is a positive step for the company's financial position, the document also acknowledges potential risks and dilution for investors, resulting in a neutral sentiment score.

Positives

• The offering aims to provide Aptevo with additional capital to advance its clinical programs and develop its product candidates.
• The use of pre-funded warrants allows certain investors to participate without exceeding ownership limitations.
• The company has flexibility in using the net proceeds for working capital and general corporate purposes.
• Aptevo has two clinical candidates and three preclinical candidates currently in development.

Negatives

• Investors will experience immediate and substantial dilution in the net tangible book value per share of the common stock.
• There is no established public trading market for the pre-funded warrants or common warrants, which limits liquidity.
• The actual offering amount, placement agent fees, and proceeds to Aptevo are not presently determinable and may be substantially less than the total maximum offering amounts.
• The company may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There is no public market for the common warrants or pre-funded warrants being offered.
• The common warrants and pre-funded warrants are speculative in nature.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.
• Resales of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall.
• This offering may cause the trading price of our common stock to decrease.

Future Outlook

Aptevo intends to use the net proceeds from this offering for working capital to fund its clinical programs and general corporate purposes, including the further development of its product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents, with nine new bispecific agents approved by the FDA in the last three years and a total of 125 bispecific drug candidates currently in development.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• However, it mentions the increasing recognition of bispecific therapeutics as potent anti-cancer agents, suggesting that Aptevo's focus on developing such therapies aligns with current industry trends.
• Companies like Amgen (with Blincyto) and Roche (with Hemlibra) have successfully developed and commercialized bispecific antibodies, setting a benchmark for others in the field.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The offering could provide the company with additional resources to advance its clinical programs, potentially benefiting patients.
• Employees may benefit from increased job security and opportunities if the company is successful in its development efforts.

Next Steps

• The company plans to initiate a dose optimization Phase 1b/2 trial in the first half of 2024 for APVO436 in combination with Venetoclax and Azacitidine.
• Aptevo and Alligator continue to investigate ALG.APV-527 for the treatment of multiple solid tumor types with 5T4-tumor expressing antigens.
• Continued development and advancement of our preclinical candidates, APVO603, APVO442, and APVO711.
• The company will seek to establish collaborative partnerships to broaden its pipeline and provide funding for research and development.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Aptevo Therapeutics, immunotherapy, cancer, clinical trials, financing, biotechnology